Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
2.660
+0.030 (1.14%)
At close: May 30, 2025, 4:00 PM
2.590
-0.070 (-2.62%)
After-hours: May 30, 2025, 7:50 PM EDT
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Shantanu Gaur |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts 01760 United States | |
| Phone | 508 647 4000 |
| Website | allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G1022 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President, Principal Financial and Accounting Officer and Director |
| Ojas A. Buch | Chief Operating Officer |
| Brendan Michael Gibbons J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Samuel G. Levy | Co-Founder |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
| Matt Wright | Vice President of People |
| Adrian Wild | Senior Vice President of International Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2025 | 424B3 | Prospectus |
| May 20, 2025 | 424B3 | Prospectus |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 8-K | Current Report |
| May 9, 2025 | EFFECT | Notice of Effectiveness |
| Apr 30, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 18, 2025 | 424B3 | Prospectus |
| Apr 18, 2025 | 424B3 | Prospectus |
| Apr 17, 2025 | SCHEDULE 13D/A | Filing |